PIRAMAL PHARMA
|
PIRAMAL PHARMA Last 5 Year Financial Ratios History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | -2.46 | 0.69 | 0.13 | -1.56 | 3.17 |
| CEPS(Rs) | 3.81 | 6.85 | 5.73 | 4.01 | 7.92 |
| DPS(Rs) | - | 0.14 | 0.11 | - | - |
| Book NAV/Share(Rs) | 60.96 | 60.89 | 59.59 | 56.76 | 56.47 |
| Tax Rate(%) | -85.13 | 78.02 | 90.06 | -55.19 | 22.48 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 8.49 | 13.35 | 12.42 | 7.75 | 13.00 |
| EBIT Margin(%) | 1.57 | 7.87 | 6.66 | 2.76 | 9.35 |
| Pre Tax Margin(%) | -1.67 | 3.90 | 1.90 | -1.48 | 6.64 |
| PAT Margin (%) | -3.10 | 0.86 | 0.19 | -2.30 | 5.15 |
| Cash Profit Margin (%) | 4.80 | 8.54 | 8.05 | 6.05 | 13.17 |
| Performance Ratios | |||||
| ROA(%) | -1.98 | 0.60 | 0.12 | -1.37 | 3.20 |
| ROE(%) | -4.04 | 1.14 | 0.24 | -2.77 | 6.11 |
| ROCE(%) | 1.24 | 6.61 | 5.07 | 1.95 | 7.10 |
| Asset Turnover(x) | 0.64 | 0.70 | 0.64 | 0.60 | 0.62 |
| Sales/Fixed Asset(x) | 0.75 | 0.84 | 0.82 | 0.80 | 0.83 |
| Working Capital/Sales(x) | 4.32 | 5.23 | 8.60 | 8.17 | 7.07 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 1.33 | 1.19 | 1.22 | 1.26 | 1.21 |
| Receivable days | 78.20 | 77.05 | 76.20 | 80.70 | 83.94 |
| Inventory Days | 93.30 | 77.13 | 74.72 | 69.11 | 65.47 |
| Payable days | 226.14 | 173.49 | 168.73 | 149.81 | 144.76 |
| Valuation Parameters | |||||
| PER(x) | -55.56 | 326.26 | 956.95 | - | - |
| PCE(x) | 35.84 | 32.76 | 22.49 | 16.66 | - |
| Price/Book(x) | 2.24 | 3.69 | 2.16 | 1.21 | - |
| Yield(%) | - | 0.06 | 0.09 | - | - |
| EV/Net Sales(x) | 2.52 | 3.71 | 2.59 | 1.89 | 0.74 |
| EV/Core EBITDA(x) | 19.72 | 21.49 | 15.40 | 15.66 | 3.98 |
| EV/EBIT(x) | 135.86 | 40.60 | 33.66 | 59.65 | 7.14 |
| EV/CE(x) | 1.64 | 2.64 | 1.69 | 1.09 | 0.46 |
| M Cap / Sales | 2.04 | 3.25 | 2.09 | 1.15 | - |
| Growth Ratio | |||||
| Net Sales Growth(%) | -3.08 | 11.99 | 15.39 | 7.97 | 3.87 |
| Core EBITDA Growth(%) | -28.15 | 15.16 | 60.74 | -30.36 | -23.03 |
| EBIT Growth(%) | -80.30 | 33.20 | 180.22 | -67.21 | -38.59 |
| PAT Growth(%) | -457.66 | 411.39 | 109.56 | -149.60 | -54.98 |
| EPS Growth(%) | -456.91 | 410.84 | 108.62 | -149.29 | -62.24 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.68 | 0.59 | 0.58 | 0.81 | 0.60 |
| Current Ratio(x) | 1.50 | 1.53 | 1.25 | 1.26 | 1.33 |
| Quick Ratio(x) | 0.87 | 0.93 | 0.75 | 0.82 | 0.89 |
| Interest Cover(x) | 0.48 | 1.98 | 1.40 | 0.65 | 3.45 |
| Total Debt/Mcap(x) | 0.30 | 0.16 | 0.27 | 0.67 | - |
Compare Financial Ratios of peers of PIRAMAL PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| PIRAMAL PHARMA | ₹23,264.5 Cr | -1.3% | 6.7% | -14.8% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹467,870.0 Cr | 0.8% | 8.3% | 17.1% | Stock Analytics | |
| DIVIS LABORATORIES | ₹194,316.0 Cr | 7.1% | 9% | 4.2% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹169,316.0 Cr | 2% | 12.1% | 49.6% | Stock Analytics | |
| CIPLA | ₹115,477.0 Cr | -0.7% | 4.1% | -3.6% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹102,156.0 Cr | -1.7% | -4.2% | -3.1% | Stock Analytics | |
PIRAMAL PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| PIRAMAL PHARMA | -1.3% |
6.7% |
-14.8% |
| SENSEX | 0.6% |
1.2% |
-7.8% |
You may also like the below Video Courses
